



AF11624

PATENTS
IN THE UNITED STATES PATENT AND TRADEMARK OFFICEApplicant: Schrimpf, *et al.*

Serial No.: 09/833,914

Filed: April 12, 2001

For: DIAZABICYCLIC CENTRAL
NERVOUS SYSTEM ACTIVE
AGENTS

Examiner: B. L. Coleman

Group Art Unit: 1624

Case No.: 6696.US.O2

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450CERTIFICATE OF MAILING (37 CFR
1.8 (a))


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

Date of Deposit: September 22, 2003


Tanya Parent

Date


TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS are the following:

1. Response to Office Action (10 Pages); and
2. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,
Schrimpf, *et al.*ABBOTT LABORATORIES
Customer No. 23492
Telephone: (847) 937-8272
Facsimile: (847) 938-2623
Portia Chen
Registration No. 44,075
Attorney for Applicants